Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 28, 2017; 23(24): 4354-4368
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4354
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4354
Figure 7 Naringenin effect on macroscopic and microscopic hepatic architecture in CCl4-treated rats.
Macroscopic aspect of livers in control rats (A), carbon tetrachloride (CCl4)-treated rats (B), CCl4 plus naringenin rats (CCl4 + NAR) (C), and NAR alone rats (D). Hematoxylin and Eosin stain in livers of control rats (E), CCl4-treated rats (F), CCl4 + NAR rats (G), and rats administered with NAR alone (H). Masson’s trichromic staining in livers of control rats (I), CCl4-treated rats (J), CCl4 + NAR (K), and NAR alone rats (L). Bar scale = 50 μm. Magnification × 100.
- Citation: Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368
- URL: https://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i24.4354